# SUNLIGHT (NCT04737187)

> Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04737187
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Taiho Oncology, Inc.
- Conditions: Refractory Metastatic Colorectal Cancer
- Interventions: Trifluridine/Tipiracil; Bevacizumab
- Enrollment: 492
- Primary outcome: Overall Survival (OS)
- Primary outcome: Survival Probability at 6 Months
- Primary outcome: Survival Probability at 12 Months
- Primary outcome: Survival Probability at 18 Months

## Indexed commentary on SUNLIGHT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sunlight-nct04737187